Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Assets (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Non-Current Assets readings, the most recent being $65.5 million for Q1 2026.

  • Quarterly Non-Current Assets rose 83.26% to $65.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $212.4 million through Mar 2026, up 45.5% year-over-year, with the annual reading at $76.6 million for FY2025, 111.35% up from the prior year.
  • Non-Current Assets hit $65.5 million in Q1 2026 for Ovid Therapeutics, down from $76.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $76.6 million in Q4 2025 and bottomed at $21.0 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $36.1 million, with a median of $35.0 million recorded in 2025.
  • The largest annual shift saw Non-Current Assets soared 2546.02% in 2022 before it decreased 7.05% in 2025.
  • Ovid Therapeutics' Non-Current Assets stood at $23.9 million in 2022, then skyrocketed by 44.14% to $34.4 million in 2023, then rose by 5.22% to $36.2 million in 2024, then soared by 111.35% to $76.6 million in 2025, then fell by 14.48% to $65.5 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Non-Current Assets are $65.5 million (Q1 2026), $76.6 million (Q4 2025), and $35.0 million (Q3 2025).